What the Justice Department Says Happened After the Indictment
The Justice Department has laid out a sequence in a new announcement that is worth reading slowly, because it describes a gap in how federal health programs stop money from moving.
According to the department's July 21 announcement, Khalid Satary, 54, was charged by indictment in 2019 in the Eastern District of Louisiana over laboratories that billed Medicare more than $547 million between 2016 and 2019 for expensive and medically unnecessary cancer genetic tests.
Following that indictment, prosecutors say, Satary was released on bond over the government's objection, with a condition not to work in the health care field. "While on bond, Satary allegedly conspired with Houston-based laboratories in Texas to continue submitting fraudulent genetic testing claims to Medicare," the department stated.
A federal arrest warrant was issued in December 2022 after he allegedly violated release conditions and failed to appear for a court hearing. He is alleged to have then fled the country. He was apprehended in the Middle East on July 20, 2026, in possession of a fake Mexican passport under a false name, and made his initial appearance in the Eastern District of Virginia the following day.
The Gap Between a Criminal Charge and a Billing Privilege
The accountability question here is structural rather than partisan, and it is one that Medicare beneficiaries and taxpayers have a direct stake in.
An indictment is a criminal charge. A Medicare billing privilege is an administrative enrollment held by a provider or supplier. They are separate systems with separate triggers. A court can order a defendant not to work in health care, as happened here, but that condition binds the person, not necessarily every corporate entity that submits claims.
That is the mechanism the department describes: claims allegedly continued to flow through Houston-area laboratories after the person prosecutors identified as the organizer had already been charged and ordered out of the industry.
The scale of the original scheme illustrates why the gap matters. Prosecutors allege Satary conspired with dozens of patient recruiters, telemarketing call centers and telemedicine companies, using deceptive marketing and illegal kickbacks to generate cancer genetic test samples that reimbursed between $10,000 and $20,000 each. The HHS Office of Inspector General identifies the laboratories involved as Performance Laboratories in Oklahoma, Lazarus Services in Louisiana and Clio Labs in Georgia, and says the tests were solicited through telemarketing and health fairs, then approved by telemedicine doctors who often never spoke with the patients.
In connection with the indictment, the government seized 16 bank accounts and restrained real estate.
Why This Matters for Medicare Households
Genetic testing fraud is not an abstraction for older adults. The scheme described in this case worked by collecting Medicare numbers at health fairs and through cold calls, in exchange for a cancer screening presented as free.
"Medicare fraud targets vulnerable populations and defrauds taxpayers out of millions of dollars," said U.S. Attorney David I. Courcelle for the Eastern District of Louisiana. "In this case, the defendant allegedly targeted elderly, disabled and other vulnerable consumers, nationwide, luring them into a fraudulent scheme that generated massive taxpayer losses."
Acting Deputy Inspector General for Investigations Miranda L. Bennett of HHS-OIG said the investigation "uncovered an alleged scheme that exploited vulnerable Medicare beneficiaries through medically unnecessary genetic testing and caused hundreds of millions of dollars in losses to federal health programs."
The household consequences are practical. A beneficiary whose Medicare number is used for an unnecessary test may find that a legitimately needed test later hits a frequency limit or is denied. Records can show tests a patient never received. And the aggregate cost of these schemes flows back into program spending that shapes premiums and coverage decisions.
Beneficiaries can protect themselves with a few concrete steps. Treat Medicare numbers like credit card numbers and do not give them to anyone offering free screenings at events, by phone or door to door. Review every Medicare Summary Notice or Explanation of Benefits and look for tests, dates, or providers you do not recognize. Report unfamiliar claims to 1-800-MEDICARE, and report suspected fraud to the HHS-OIG hotline at 1-800-HHS-TIPS. State Health Insurance Assistance Programs offer free counseling on appeals and billing disputes.
Legitimate genetic testing ordered by your own treating physician for a documented clinical reason is a normal, covered part of care, and nothing here should discourage patients from following a doctor's recommendation.
What Is Proven, What Remains Alleged
This distinction should not be buried. Satary has not been convicted of anything. He is charged with conspiracy to commit health care fraud and wire fraud, health care fraud, conspiracy to defraud the United States and to pay and receive illegal kickbacks and bribes, and conspiracy to commit money laundering. If convicted, he faces maximum penalties of 20 years on the wire fraud and money laundering conspiracy counts, 10 years on the health care fraud counts and five years on the kickback conspiracy count.
The claim that billing continued while he was on bond is an allegation contained in the department's announcement, not an adjudicated finding. The Justice Department has not published the volume of claims allegedly submitted during that period, has not identified the Houston laboratories by name, and has not said whether those laboratories or their operators face separate charges.
It is also unclear from the public record what, if any, administrative action the Centers for Medicare and Medicaid Services took against the associated laboratory enrollments during that window. That is the open oversight question this case raises.
What Happens Next
The case returns to the Eastern District of Louisiana, where the 2019 indictment was filed, after the initial appearance in Virginia. Assistant Chief Justin M. Woodard and Trial Attorney Andrew Tamayo of the Criminal Division's Fraud Section are prosecuting, with assistance from the Southern District of Florida. The FBI and HHS-OIG are investigating.
Court dates have not been publicly scheduled. The Justice Department noted that the arrest was the third capture from the FBI's Most Wanted Fraudsters list, created June 4, in five weeks. Broader enforcement context is available in the department's 2026 National Health Care Fraud Takedown, which charged 455 defendants in connection with more than $6.5 billion in alleged fraud.
MedicalDaily will monitor court filings, any charges involving the Houston-area laboratories, and any CMS policy response addressing billing privileges held by entities tied to indicted individuals.
Frequently Asked Questions
What did the Justice Department announce? That Khalid Satary, indicted in 2019 over a $547 million Medicare genetic testing scheme, was arrested overseas on July 20, 2026, and returned to U.S. custody after more than three years as a fugitive.
What is the allegation about billing while on bond? Prosecutors say he was released on bond over the government's objection with a condition not to work in health care, and that while on bond he allegedly conspired with Houston-based laboratories to keep submitting fraudulent genetic testing claims to Medicare.
Has he been convicted? No. All of the described conduct remains an allegation, and he faces charges that have not been tried.
How did the alleged scheme reach patients? Through telemarketing calls and health fairs offering cancer genetic tests, with orders signed by telemedicine doctors who often never spoke with the patients, according to HHS-OIG.
How can Medicare beneficiaries protect themselves? Do not share Medicare numbers in exchange for free screenings, review every Explanation of Benefits, and report unrecognized claims to 1-800-MEDICARE or 1-800-HHS-TIPS.
Does this mean genetic testing is a scam? No. Genetic testing ordered by your own physician for a documented clinical reason is legitimate and covered. The alleged fraud involved tests solicited by marketers rather than ordered by treating doctors.
What happens next in the case? The prosecution proceeds in the Eastern District of Louisiana. No trial date has been publicly announced.
